Clemens Zwergel

Pubblicazioni

Titolo Pubblicato in Anno
Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells CLINICAL EPIGENETICS 2019
Sirtuins as drug targets Epigenetic Drug Discovery 2019
Epigenetic Pharmacology in Regenerative Medicine (Epi-Drugs) Epigenetics and Regeneration 2019
Amphetamine and the Smart Drug 3,4-Methylenedioxypyrovalerone (MDPV) Induce Generalization of Fear Memory in Rats FRONTIERS IN MOLECULAR NEUROSCIENCE 2019
Lysine methyltransferases and their inhibitors Chemical Epigenetics 2019
HDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal OPEN ACCESS SCIENTIFIC REPORTS 2018
Effects of class II-selective histone deacetylase inhibitor on neuromuscular function and disease progression in SOD1-ALS mice NEUROSCIENCE 2018
Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells PHILOSOPHICAL TRANSACTIONS - ROYAL SOCIETY. BIOLOGICAL SCIENCES 2018
Trends of LSD1 inhibitors in viral infections FUTURE MEDICINAL CHEMISTRY 2018
Nucleocytoplasmic export of HDAC5 and SIRT2 downregulation: two epigenetic mechanisms by which antidepressants enhance synaptic plasticity markers PSYCHOPHARMACOLOGY 2018
A quinoline-based DNA methyltransferase inhibitor as a possible adjuvant in osteosarcoma therapy MOLECULAR CANCER THERAPEUTICS 2018
Six years (2012-2018) of researches on catalytic EZH2 inhibitors: the boom of the 2-pyridone compounds THE CHEMICAL RECORD 2018
Application of Small Epigenetic Modulators in Pediatric Medulloblastoma FRONTIERS IN PEDIATRICS 2018
Towards the development of activity-based probes for detection of lysine-specific demethylase-1 activity. BIOORGANIC & MEDICINAL CHEMISTRY 2017
Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2017
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy CLINICAL EPIGENETICS 2017
EZH2 inhibitors: a patent review (2014-2016) EXPERT OPINION ON THERAPEUTIC PATENTS 2017
The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells ONCOTARGET 2017
Effect of Class II HDAC inhibition on glutamate transporter expression and survival in SOD1-ALS mice NEUROSCIENCE LETTERS 2017
Metabolite profiling of ascidian Styela plicata using LC–MS with multivariate statistical analysis and their antitumor activity JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 2017

ERC

  • LS1_13

KET

  • Life-science technologies & biotechnologies

Interessi di ricerca

Dr. Clemens Zwergel is currently an Assistant Professor (RTD-A) at the Sapienza University of Rome. In the last years he proved to be a true European citizen: he moved after his license to practise as Pharmacist from his country of origin (Germany) to Exter (UK) for a Diploma in Pharmaceutical Sciences. Before moving to Italy, he was then a MarieCurie fellow in France (Metz) where he obtained his EuroPhD within the RedCat network. Since 2010, his main research interest lies mainly in the design and synthesis of analogues of natural compounds as well as modulators of epigenetic enzymes with potential applications in cancer, neurodegenerative, metabolic, and infectious diseases resulting in more than 70 publications (https://www.scopus.com/authid/detail.uri?authorId=37017859900). Communication and divulging science are very important aspects for a researcher, thus I would like to increase the visibility of Medicinal Chemistry and the EFMC to the scientific community as well as the general public as well as strengthen the European collaborations together with the other team members.

Keywords

medicinal chemistry

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma